← All trials
NCT06861244
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 6, 2025
- Primary completion
- Sep 30, 2030
- Completion date
- Mar 31, 2032
- First posted
- Mar 6, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 70
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Hackensack University Medical CenterOfficial
- University of California, San FranciscoOfficial
- The Pacific Pediatric Neuro-Oncology ConsortiumCollaborator
- Solving Kids’ CancerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.